aTyr Pharma (NASDAQ:ATYR) Stock Rating Upgraded by Wall Street Zen

aTyr Pharma (NASDAQ:ATYR) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Sunday.

ATYR has been the subject of several other research reports. Jefferies Financial Group reiterated a “buy” rating on shares of aTyr Pharma in a research report on Friday, March 6th. Weiss Ratings restated a “sell (d-)” rating on shares of aTyr Pharma in a research report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $25.67.

aTyr Pharma Trading Down 2.0%

NASDAQ ATYR opened at $0.85 on Friday. The stock has a market capitalization of $83.34 million, a price-to-earnings ratio of -1.08 and a beta of 0.55. The business’s 50 day moving average is $0.85 and its two-hundred day moving average is $1.26. aTyr Pharma has a 12-month low of $0.64 and a 12-month high of $7.29.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. Equities analysts forecast that aTyr Pharma will post -0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On aTyr Pharma

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of aTyr Pharma by 21.0% in the 3rd quarter. Vanguard Group Inc. now owns 5,630,935 shares of the company’s stock worth $4,060,000 after acquiring an additional 975,887 shares during the period. UBS Group AG raised its holdings in aTyr Pharma by 158.1% during the third quarter. UBS Group AG now owns 4,505,955 shares of the company’s stock worth $3,249,000 after purchasing an additional 2,760,238 shares during the last quarter. Octagon Capital Advisors LP boosted its position in aTyr Pharma by 7.5% during the second quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company’s stock worth $19,367,000 after purchasing an additional 268,000 shares in the last quarter. GSA Capital Partners LLP boosted its position in aTyr Pharma by 272.2% during the fourth quarter. GSA Capital Partners LLP now owns 2,630,638 shares of the company’s stock worth $2,060,000 after purchasing an additional 1,923,907 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in aTyr Pharma by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 2,283,717 shares of the company’s stock valued at $1,789,000 after purchasing an additional 105,514 shares during the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.